Document is current
Any future updates will be listed below
-
Authors
Shakiba, Mojdeh
Tuveson, David A. https://orcid.org/0000-0002-8017-2712
-
Funding
Funding for this research was provided by:
Lustgarten Foundation (50340801)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U01CA224013, P30CA045508)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (R01CA2419002)
U.S. Department of Defense (HT9425-24-1-0091)
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 13 March 2025
First Online: 22 April 2025
Competing interests
: D.A.T. is a member of the Scientific Advisory Board of and receives stock options from Leap Therapeutics, Surface Oncology, Sonata Therapeutics, Mestag Therapeutics and Xilis outside of the submitted work. D.A.T. is a scientific cofounder of Mestag Therapeutics. D.A.T. has received research grant support from Fibrogen, Mestag and ONO Therapeutics. D.A.T. receives grant funding from the Lustgarten Foundation, the NIH, the Pershing Square Foundation and the Thompson Foundation. M.S. declares no competing interests.
